ONK Therapeutics - Crunchbase Company Profile & Funding

Q: Where is ONK Therapeutics's headquarters?

ONK Therapeutics is located in Barna, Galway, Ireland.

Q: Who invested in ONK Therapeutics?

ONK Therapeutics has 3 investors including Cormorant Asset Management And Acorn Bioventures.

Q: When was the last funding round for ONK Therapeutics?

ONK Therapeutics closed its last funding round on obfuscated from a Series A round.

Q: How much funding has ONK Therapeutics raised to date?

ONK Therapeutics has raised obfuscated.

Overview

ONK Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About ONK Therapeutics

CB Rank

92129

ONK Therapeutics is an innovative cell therapy organisation.

Founded

obfuscation

Private

Series A

Barna, Galway, Ireland

11-50

www.onktherapeutics.com/

Biotechnology

Health Care

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Key People

Michael O'Dwyer: Founder and CSO
Tony Killarney: Founder & Director

Details

Legal Name

ONK Therapeutics Limited

Operating Status

Active

Company Type

For Profit

Founders

Michael O'Dwyer, Tony Killarney

About the Company

ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of off-the-shelf, optimally engineered natural killer (NK) cell therapies targeting both hematological malignancies and solid tumors.

Contact Email

info@onktherapeutics.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

CISH Knockout (KO) in NK Cells

Genetically modified NK cells with the CISH gene deleted to enhance their metabolic profile, persistence, and cytotoxicity for cancer therapy.

ONKT102

An off-the-shelf NK cell therapy combining an optimized affinity CD38 CAR and a TRAIL variant targeting DR5 for treating relapsed/refractory multiple myeloma.

Research & Development

ONK Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A
obfuscated obfuscation	Series A - ONK Therapeutics	3	obfuscated obfuscation	Acorn Bioventures, ALSHC	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Cormorant Asset Management	—	Series A - ONK Therapeutics	—
Cormorant Asset Management	—	Series A - ONK Therapeutics	—
Cormorant Asset Management	—	Series A - ONK Therapeutics	—
Cormorant Asset Management	—	Series A - ONK Therapeutics	—
Cormorant Asset Management	—	Series A - ONK Therapeutics	—